Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder—outcome measures beyond symptom control and clinical trials

Lancet Psychiatry

Fecha de publicación: June 2019

DOI: https://doi.org/10.1016/S2215-0366(19)30096-3

Autores: Prof Ian C K Wong, PhD., Prof Tobias Banaschewski, MD
Prof Jan Buitelaar, MD., Samuele Cortese, MD., Döpfner Manfred Döpfner, PhD., Prof Emily Simonoff, MD., et al.

Background: Although pharmacological therapies are recommended as a key component in the treatment of attention-deficit hyperactivity disorder, their use continues to prompt intense debate. Despite considerable research efforts, several gaps in the knowledge base and several questions over the quality of evidence exist.

Seguir leyendo

Enviar comentario